Navigation Links
Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Date:9/18/2007

ly conducting a Phase 1 trial in Canada with a second p38 kinase inhibitor resulting from the collaborative research program.

Under the terms of the companies' ongoing collaboration, Pharmacopeia will receive milestone payments for the p38 compounds in the program to the extent the program progresses through clinical development, and royalty payments for any product from the program that reaches the marketplace. Bristol-Myers Squibb is solely responsible for further development and commercialization of the therapeutic candidate.

ABOUT PHARMACOPEIA

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which a Phase 2 clinical trial is underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes two partnered programs that have advanced into Phase 2 clinical trials targeting chronic obstructive pulmonary disease (COPD) and psoriasis and two partnered programs in Phase 1 clinical trials targeting oncology and inflammatory disease. Four additional partnered compounds are in preclinical development. Pharmacopeia's current strategic alliances are with Cephalon, GlaxoSmithKline, Organon and Wyeth.

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based u
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 Patterson Medical, ... (Nasdaq: PDCO ), is now an independent ... acquisition of Patterson Medical by Madison Dearborn Partners ... its name for a transition period before rebranding ... and sports medicine products.  With the focused resources ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... to their offering. Developed by Novo ... Novolog) is an important drug for the treatment ... as a fast- acting insulin analog, starts working ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... 2011 Cardinal Health today announced that its board of directors ... on April 15 to shareholders of record on April 1. This ... About Cardinal Health Headquartered in ... a $99 billion health care services company that improves ...
... ANGELES, Feb. 1, 2011 A breakthrough in stroke ... in stroke survivors has published today. In the February ... the first human results of a new method ... reported. Rapid improvement in impaired motor function, gait, hand ...
Cached Medicine Technology:Cardinal Health Declares Regular Quarterly Dividend 2Inflammation Identified as New Therapeutic Target Years After Stroke 2
(Date:8/28/2015)... ... 2015 , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance ... A Mission” benefit concert in Mendon, IL. Held in the Show Barn at the ... music education programs in the underfunded local school districts of Mendon at neighboring Quincy, ...
(Date:8/28/2015)... ... 28, 2015 , ... Altima Technologies, Inc., the maker of ... center assets and audio-video devices, recently released Visio Stencils for the following product ... Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data Systems Virtual ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International ... adolescent residential, counseling, day treatment and intensive family based services. , By pursuing ... quality and its pursuit of excellence. As a nonprofit charity for more than ...
(Date:8/28/2015)... ... , ... Northridge dentists Dr. Elyson and Dr. Assili are now ... currently receive a one hour treatment of this teeth whitening option. Zoom whitening ... of unique features that can turn teeth up to nine shades whiter. Effective on ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... which is dedicated to distributing health information technology innovation to transform quality and ... Results of the survey will be de-identified and aggregated before being publicly shared ...
Breaking Medicine News(10 mins):Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... , , ... an effort to help brokers, employers and employees reap the ... carbon footprint, The Guardian Life Insurance Company of America ... and small businesses, is launching a campaign focusing on its ...
... the University of Helsinki, Finland, and the Paul Scherrer ... structure of the ligand binding domain of a vascular ... of its ligands (VEGF-C). Cancer cells require access ... metastasis. By releasing VEGFs, cancer cells stimulate the surrounding ...
... the amount teenage minority boys smoke but does not ... a new study from the Indiana University School of ... March 2010 issue of the American Journal of ... under "First Look" at http://ajph.aphapublications.org/first_look.shtml . While ...
... study finds, , TUESDAY, Jan. 19 (HealthDay News) -- The more ... it, a new study finds. , The finding came from a ... diet plans. The simpler plan provided shopping lists for dieters and ... assigned point values to every food and instructed participants to eat ...
... EET Reno is ... of a Rapid Prototyping line increases the flexibility and services available to its new and ... (PRWEB) January ... high speed Rapid Prototyping line for its plant in Reno, Nevada. This strategic addition ...
... ... rapidly-growing network of retailers carrying its over-the-counter (OTC) pain reliever, Cobroxin, by expanding ... national sponsorships, and additional print advertising. , ... Delray Beach, FL (Vocus) January 19, 2010 ...
Cached Medicine News:Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4Health News:Minority teen boys smoke more when they perceive discrimination; girls do not 2Health News:Complex Weight-Loss Plans Erode Dieters' Resolve 2Health News:EE Technologies Adds High Speed Rapid Prototyping Line in Reno 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 2Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 3Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 4Health News:XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow 5
Guthrie fixation hook, sharp double prongs....
... lenses will feel good when you first put ... 12 hours later? Many lenses start to feel ... look blurry. But with Proclear lenses, youll enjoy ... This exceptional level of comfort is made possible ...
Designed to allow very easy handling....
The convenience of disposable type lenses available in a wide variety of options. Recommended replacement schedule: one week for extended wear, two weeks for daily wear....
Medicine Products: